Neurocrine Biosciences (NBIX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $142.06 -0.86%
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's capital-raising plans expose a major weakness in the AI boom
- Lockheed Martin (LMT) PT Raised to $692 at UBS
- Honeywell International (HON) PT Raised to $256 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
